vs
Side-by-side financial comparison of Medpace Holdings, Inc. (MEDP) and Reynolds Consumer Products Inc. (REYN). Click either name above to swap in a different company.
Reynolds Consumer Products Inc. is the larger business by last-quarter revenue ($1.0B vs $708.5M, roughly 1.5× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 11.4%, a 7.7% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 1.2%). Reynolds Consumer Products Inc. produced more free cash flow last quarter ($200.0M vs $188.1M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 11.4%).
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
The Rival Company is an American manufacturer of small appliances that produces products under the Bionaire, Crock-Pot, Fasco, Patton, Pollenex, Rival, Simer, and White Mountain brands. It became a wholly owned subsidiary of Holmes Products Corp. in 1999, and later became a brand of Sunbeam Products, a subsidiary of Jarden Corporation, which purchased Holmes in 2005. Jarden, in turn, merged with Newell Rubbermaid in 2016. It is now part of the Newell Brands company.
MEDP vs REYN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $708.5M | $1.0B |
| Net Profit | $135.1M | $118.0M |
| Gross Margin | — | 25.7% |
| Operating Margin | 21.6% | 14.8% |
| Net Margin | 19.1% | 11.4% |
| Revenue YoY | 32.0% | 1.2% |
| Net Profit YoY | 15.5% | -1.7% |
| EPS (diluted) | $4.65 | $0.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $708.5M | $1.0B | ||
| Q3 25 | $659.9M | $931.0M | ||
| Q2 25 | $603.3M | $938.0M | ||
| Q1 25 | $558.6M | $818.0M | ||
| Q4 24 | $536.6M | $1.0B | ||
| Q3 24 | $533.3M | $910.0M | ||
| Q2 24 | $528.1M | $930.0M | ||
| Q1 24 | $511.0M | $833.0M |
| Q4 25 | $135.1M | $118.0M | ||
| Q3 25 | $111.1M | $79.0M | ||
| Q2 25 | $90.3M | $73.0M | ||
| Q1 25 | $114.6M | $31.0M | ||
| Q4 24 | $117.0M | $120.0M | ||
| Q3 24 | $96.4M | $86.0M | ||
| Q2 24 | $88.4M | $97.0M | ||
| Q1 24 | $102.6M | $49.0M |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 25.0% | ||
| Q2 25 | — | 24.1% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 26.3% | ||
| Q2 24 | — | 27.5% | ||
| Q1 24 | — | 24.1% |
| Q4 25 | 21.6% | 14.8% | ||
| Q3 25 | 21.5% | 11.0% | ||
| Q2 25 | 20.9% | 10.2% | ||
| Q1 25 | 20.3% | 5.1% | ||
| Q4 24 | 23.4% | 15.5% | ||
| Q3 24 | 21.1% | 12.4% | ||
| Q2 24 | 19.9% | 12.4% | ||
| Q1 24 | 20.4% | 7.8% |
| Q4 25 | 19.1% | 11.4% | ||
| Q3 25 | 16.8% | 8.5% | ||
| Q2 25 | 15.0% | 7.8% | ||
| Q1 25 | 20.5% | 3.8% | ||
| Q4 24 | 21.8% | 11.7% | ||
| Q3 24 | 18.1% | 9.5% | ||
| Q2 24 | 16.7% | 10.4% | ||
| Q1 24 | 20.1% | 5.9% |
| Q4 25 | $4.65 | $0.55 | ||
| Q3 25 | $3.86 | $0.38 | ||
| Q2 25 | $3.10 | $0.35 | ||
| Q1 25 | $3.67 | $0.15 | ||
| Q4 24 | $3.67 | $0.57 | ||
| Q3 24 | $3.01 | $0.41 | ||
| Q2 24 | $2.75 | $0.46 | ||
| Q1 24 | $3.20 | $0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $497.0M | $147.0M |
| Total DebtLower is stronger | — | $1.6B |
| Stockholders' EquityBook value | $459.1M | $2.3B |
| Total Assets | $2.0B | $4.9B |
| Debt / EquityLower = less leverage | — | 0.70× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $497.0M | $147.0M | ||
| Q3 25 | $285.4M | $53.0M | ||
| Q2 25 | $46.3M | $57.0M | ||
| Q1 25 | $441.4M | $58.0M | ||
| Q4 24 | $669.4M | $137.0M | ||
| Q3 24 | $656.9M | $96.0M | ||
| Q2 24 | $510.9M | $101.0M | ||
| Q1 24 | $407.0M | $135.0M |
| Q4 25 | — | $1.6B | ||
| Q3 25 | — | $1.6B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.8B | ||
| Q1 24 | — | $1.8B |
| Q4 25 | $459.1M | $2.3B | ||
| Q3 25 | $293.6M | $2.2B | ||
| Q2 25 | $172.4M | $2.1B | ||
| Q1 25 | $593.6M | $2.1B | ||
| Q4 24 | $825.5M | $2.1B | ||
| Q3 24 | $881.4M | $2.1B | ||
| Q2 24 | $763.6M | $2.0B | ||
| Q1 24 | $671.5M | $2.0B |
| Q4 25 | $2.0B | $4.9B | ||
| Q3 25 | $1.8B | $4.9B | ||
| Q2 25 | $1.6B | $4.9B | ||
| Q1 25 | $1.9B | $4.8B | ||
| Q4 24 | $2.1B | $4.9B | ||
| Q3 24 | $2.1B | $4.8B | ||
| Q2 24 | $1.9B | $4.9B | ||
| Q1 24 | $1.8B | $4.9B |
| Q4 25 | — | 0.70× | ||
| Q3 25 | — | 0.75× | ||
| Q2 25 | — | 0.76× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | 0.79× | ||
| Q3 24 | — | 0.84× | ||
| Q2 24 | — | 0.87× | ||
| Q1 24 | — | 0.92× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $192.7M | $237.0M |
| Free Cash FlowOCF − Capex | $188.1M | $200.0M |
| FCF MarginFCF / Revenue | 26.6% | 19.3% |
| Capex IntensityCapex / Revenue | 0.6% | 3.6% |
| Cash ConversionOCF / Net Profit | 1.43× | 2.01× |
| TTM Free Cash FlowTrailing 4 quarters | $681.9M | $316.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $192.7M | $237.0M | ||
| Q3 25 | $246.2M | $93.0M | ||
| Q2 25 | $148.5M | $91.0M | ||
| Q1 25 | $125.8M | $56.0M | ||
| Q4 24 | $190.7M | $182.0M | ||
| Q3 24 | $149.1M | $124.0M | ||
| Q2 24 | $116.4M | $84.0M | ||
| Q1 24 | $152.7M | $99.0M |
| Q4 25 | $188.1M | $200.0M | ||
| Q3 25 | $235.5M | $48.0M | ||
| Q2 25 | $142.4M | $51.0M | ||
| Q1 25 | $115.8M | $17.0M | ||
| Q4 24 | $183.0M | $141.0M | ||
| Q3 24 | $138.5M | $93.0M | ||
| Q2 24 | $103.5M | $65.0M | ||
| Q1 24 | $147.2M | $70.0M |
| Q4 25 | 26.6% | 19.3% | ||
| Q3 25 | 35.7% | 5.2% | ||
| Q2 25 | 23.6% | 5.4% | ||
| Q1 25 | 20.7% | 2.1% | ||
| Q4 24 | 34.1% | 13.8% | ||
| Q3 24 | 26.0% | 10.2% | ||
| Q2 24 | 19.6% | 7.0% | ||
| Q1 24 | 28.8% | 8.4% |
| Q4 25 | 0.6% | 3.6% | ||
| Q3 25 | 1.6% | 4.8% | ||
| Q2 25 | 1.0% | 4.3% | ||
| Q1 25 | 1.8% | 4.8% | ||
| Q4 24 | 1.4% | 4.0% | ||
| Q3 24 | 2.0% | 3.4% | ||
| Q2 24 | 2.4% | 2.0% | ||
| Q1 24 | 1.1% | 3.5% |
| Q4 25 | 1.43× | 2.01× | ||
| Q3 25 | 2.22× | 1.18× | ||
| Q2 25 | 1.65× | 1.25× | ||
| Q1 25 | 1.10× | 1.81× | ||
| Q4 24 | 1.63× | 1.52× | ||
| Q3 24 | 1.55× | 1.44× | ||
| Q2 24 | 1.32× | 0.87× | ||
| Q1 24 | 1.49× | 2.02× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
REYN
| Reynolds Cooking And Baking | $397.0M | 38% |
| Hefty Waste And Storage | $247.0M | 24% |
| Tableware Products | $229.0M | 22% |
| Presto Products | $164.0M | 16% |
